Mad Hedge Biotech and Healthcare Letter
December 29, 2022
Fiat Lux
Featured Trade:
(A PROMISING START TO 2023)
(JNJ), (PFE), (MRNA), (ABMD)
Mad Hedge Biotech and Healthcare Letter
December 29, 2022
Fiat Lux
Featured Trade:
(A PROMISING START TO 2023)
(JNJ), (PFE), (MRNA), (ABMD)
Investors will be grateful to finally leave 2022 behind as the markets weathered a challenging year. For 2023, we can anticipate much of the same, at least in the first six months, which is why it’s crucial to fill your portfolio with high-quality blue-chip stocks.
Johnson & Johnson (JNJ) fits this description.
With $469 billion in market capitalization, JNJ is the biggest drugmaker across the globe, easily surpassing its peers by over $100 billion. Its product portfolio is practically unrivaled, with the company catching up in the COVID-19 vaccine race and matching the pace of Pfizer (PFE) and Moderna (MRNA). More importantly, the company has more than a dozen treatments that are on pace to go beyond $1 billion in sales this 2022.
In the third quarter of 2022, JNJ’s revenue climbed by 1.94% year-over-year to reach $23.79 billion, beating Wall Street estimates by $357.93 million. The company also started to spend more on R&D, particularly for the expansion of its medtech sector.
Recently, JNJ closed the deal to acquire Abiomed (ABMD), a leader in the manufacture of heart pump solutions, to boost its medtech segment.
This acquisition is in line with JNJ’s plan to separate its consumer products division from its pharmaceutical and medtech segments. The addition of Abiomed aligns with JNJ’s plan to integrate a smart data approach in the creation and development of new drugs. The company is also looking into leveraging new technology to bolster its medical device division.
After the split is completed, JNJ is projected to become a $60 billion biopharmaceutical entity by 2025. The primary growth drivers would be its major brands and strategic product launches. Meanwhile, the medtech segment is expected to rack up sales as well since its growth will no longer be hampered by the consumer health division, which typically faces litigations.
Specifically, Abiomed will bring its lead product, Impella, to JNJ’s pipeline, which would be an excellent addition to its cardiovascular devices portfolio. This would be a promising revenue stream for the company since the cardiovascular devices market is estimated to climb at a CAGR of 6.9%. It is projected to expand from a market size worth $54.08 billion in 2021 to $86.27 billion by 2028.
As for Impella, this smart implantable pump is anticipated to rake in more than $3.8 billion in revenue by 2031.
The split is a good business decision for JNJ. In the nine months leading to October 2022, pharmaceutical sales were noted to be at their peak at $39.4 billion. JNJ also unveiled more innovative therapeutics in this segment, including CAR-T meds and gene therapies, on top of expanded indications for well-established treatments and investigational drugs.
Some of the treatments poised for potential blockbuster status in 2023 are oncology drugs Darzalex, pulmonary hypertension medication Opsumit, immunology treatment Remicade, and cardiovascular drug Xarelto. The company also submitted multiple myeloma treatment Talquetamab for regulatory approval next year.
Apart from these, JNJ is expected to unveil at least 14 more new treatments that hold a sales potential of over $1 billion each. Meanwhile, half of the candidates are projected to rake in $5 billion or more in sales.
In comparison, the consumer health segment recorded $11.1 billion, indicating a 1.1% slide year over year.
These reports show why the news of the company's split comes as a relief for many of its investors, especially in light of how impressive its pharmaceutical business has been performing as of late. Considering that JNJ is in dire need of evolving while integrating groundbreaking technology, keeping its pharmaceutical and medtech segments tied to its consumer health division would inevitably drag sales down.
Overall, JNJ remains an excellent choice for those looking for high-quality stocks to add to their portfolio. However, it would be advisable to buy after the split. This is because the share price would most likely drop by then, offering us the chance to invest in a company geared towards the medtech and pharmaceutical space.
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visist to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds: